Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEK | Q02763 | 3/20 | 0.53 |
| ▸ | BRAF | P15056 | 5/20 | 0.51 |
| ▸ | KDR | P35968 | 3/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.51 |
| ▸ | RAF1 | P04049 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 5/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.51 |
| ▸ | BTK | Q06187 | 3/20 | 0.51 |
| ▸ | ABL1 | P00519 | 5/20 | 0.51 |
| ▸ | BCR | P11274 | 1/20 | 0.51 |
| ▸ | SRC | P12931 | 3/20 | 0.50 |
| ▸ | KIT | P10721 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.49 |
| ▸ | FES | P07332 | 1/20 | 0.49 |
| ▸ | RET | P07949 | 1/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | FLT1 | P17948 | 1/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27682252 | 0.92 | AURKA (0.56) | TEKBRAFKDRPDGFRBPDGFRA | |
| SCHEMBL4885117 | 0.89 | BTK (0.53) | TEKBRAFKDRPDGFRBPDGFRA | |
| SCHEMBL4879947 | 0.89 | BRAF (0.54) | BRAFRAF1MAPK14CYP2C9 | |
| SCHEMBL5504832 | 0.86 | MAPK14 (0.57) | TEKBRAFKDRPDGFRBPDGFRA | |
| SCHEMBL4881020 | 0.82 | MAPK14 (0.59) | TEKBRAFKDRPDGFRBPDGFRA | |
| SCHEMBL4888754 | 0.81 | BRAF (0.55) | BRAFRAF1MAPK14CYP2C9 | |
| SCHEMBL4878817 | 0.81 | MAPK14 (0.53) | TEKBRAFKDRPDGFRBPDGFRA | |
| SCHEMBL4877990 | 0.81 | MAPK14 (0.58) | TEKBRAFKDRPDGFRBPDGFRA | |
| SCHEMBL5212161 | 0.80 | MAPK14 (0.47) | TEKBRAFRAF1MAPK14 | |
| SCHEMBL4884285 | 0.80 | MAPK14 (0.66) | TEKBRAFRAF1LCKMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275022-A1 | Substituted Quinazolones as Anti-Cancer Agents | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | US | disclosed |
| EP-1761506-A1 | SUBSTITUTED QUINAZOLONES AS ANTI-CANCER AGENTS | AstraZeneca AB (SE) | 2007-03-14 | — | — | EP | disclosed |
| WO-2005123696-A1 | SUBSTITUTED QUINAZOLONES AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275022-A1 | Substituted Quinazolones as Anti-Cancer Agents | BRAF, NRAS, RAF1 | TEK 1672/4885BRAF 1/4885KDR 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.